HeraMED Limited announced that Non-Executive Director, Mr. Tal Slonim, has agreed to leave the Board. Mr. Ady Jakubovitz, VP Business Development, has announced his resignation and is transferring his roles and responsibilities. In addition, the Company also announced that Ms Anoushka Gungadin will be transitioning from a part time role to full-time as HeraMED's Director of Strategic Partnerships, Australia & New Zealand.

HeraMED is focused on executing its strategic plan for the commercialisation of HeraCARE and the Board and Management are evolving to reflect the changing needs of the Company. Initially the focus was on technology design, development, and manufacturing, and this has evolved to the current focus on commercialisation in the key target markets of Australia and USA, and scaling up resources to generate sales in all markets. The Company will continue to invest in ensuring there is appropriate expertise and resources in place to capitalise on the opportunity with significant interest, expanding pipelines as well as the expected onboarding of new customers in the coming months.

This was evidenced recently with the appointment of a highly experienced executive, formerly at Nanosonics, Mr. Keith Koby who was appointed as President of North America.